abc

NO NEWS IS GOOD NEWS

More relief with the Powerful Consistency of KISQALI*(1)

Consistent results across a broad range of HR+/HER2- eligible patients with statistically significant improvements in iDFS (EBC), PFS and OS (ABC).*(1)

* vs AI in the NATALEE study and ET in the MONALEESA studies.(1)
1. KISQALI (ribociblib). Summary of Product Characteristics.

Proven efficacy

Give more of your patients
news worth sharing

In HR+/HER2- ABC, KISQALI + ET:

For Healthcare Professionals Outside the US

KISQALI is indicated in the EU for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

KISQALI in combination with an aromatase inhibitor is indicated in the EU for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

City river view encouraging healthcare professionals to access country-specific NovartisPro information.

Visit your local HCP portal for further country specific information

This website is intended for Health Care Professionals (HCPs) outside the US and Switzerland. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information. By clicking continue you are confirming that you are an HCP.

Disclaimer: This is an international website for KISQALI® (ribociclib) and is intended for Healthcare Professionals outside the US. The information on the site is not country-specific and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. Please contact your local representative for local prescribing information via novartis.com/contacts.

Fictional healthcare professional and patient.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
Produced and funded by Novartis.

By Novartis AG
© 2025 ǀ FA-11471125-2 ǀ October 2025

Use of this website is subject to our Terms of Use